Rai Ajit Srivastava

Biography

 Dr. Srivastava is an experienced leader in research and drug discovery & development for the past three decades in multiple therapeutic areas and advancing several NCEs and biologics through preclinical testing. Served in leadership positions at Tularik Pharma (now Amgen) as head of preclinical pharmacology, Bristol-Myers Squibb as Sr. Principal Scientist, Esperion Therapeutics (ESPR) as Executive Director, and Piramal Life Sciences (India) as Executive Vice President. He has led teams to carry out preclinical discovery, pharmacology POC and MOA, PK/PD, exploratory toxicology and biomarker (efficacy and safety) studies in rodents and non-human primates. As a leader directing the discovery efforts in industries, Dr. Srivastava has helped submission of several investigational new drug applications, coordinated several project teams across functional areas, and managed collaborative studies with academic institutions and CROs. He led joint drug discovery efforts with Merck and Eli Lilly. Prior to joining the industry Dr. Srivastava served for 10 years on the faculty of the Department of Medicine, Washington University School of Medicine, St. Louis. Dr. Srivastava has a Ph.D. in Biochemistry and a diploma in MBA from India. He has published 75 peer reviewed research papers, 4 book chapters, and more than 80 presentations in international conferences and symposia. He is an adjunct Professor at the Dept. of Physiology & Pharmacology, Drexel University School of Medicine, Philadelphia.

Research Interest

 drug discovery & development,preclinical testing & discovery